

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/060945 A3

(51) International Patent Classification⁷: **A61K 47/40**,
47/36, 9/16

(21) International Application Number:
PCT/GB2004/005446

(22) International Filing Date:
23 December 2004 (23.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0329918.7 24 December 2003 (24.12.2003) GB

(71) Applicant (*for all designated States except US*):
ARCHIMEDES DEVELOPMENT LIMITED
[GB/GB]; Albert Einstein Centre, Nottingham Science
and Technology Park, University Boulevard, Nottingham
NG7 2TN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CASTLE**,
Jonathan, David [GB/GB]; West Pharmaceutical Ser-
vices Drug Delivery & Clinical Research Centre Ltd,
Albert Einstein Centre, Nottingham Science & Technol-
ogy Park, University Boulevard, Nottingham NG7 2TN
(GB). **CHENG, Yu-Hui** [CN/GB]; West Pharmaceutical
Services Drug Delivery & Clinical Research Centre Ltd,
Albert Einstein Centre, Nottingham Science & Technology
Park, University Boulevard, Nottingham NG7 2TN (GB).
JENKINS, Paul, George [GB/GB]; West Pharmaceutical
Services Drug Delivery & Clinical Research Centre Ltd,
Albert Einstein Centre, Nottingham Science & Technology
Park, University Boulevard, Nottingham NG7 2TN (GB).
SMITH, Alan [GB/GB]; West Pharmaceutical Services
Drug Delivery & Clinical Research Centre Ltd, Albert
Einstein Centre, Nottingham Science & Technology
Park, University Boulevard, Nottingham NG7 2TN (GB).

WATTS, Peter, James [GB/GB]; West Pharmaceutical
Services Drug Delivery & Clinical Research Centre Ltd,
Albert Einstein Centre, Nottingham Science & Technology
Park, University Boulevard, Nottingham NG7 2TN (GB).

(74) Agent: **CROWHURST, Charlotte**; Eric Potter Clarkson,
Park View House, 58 The Ropewalk, Nottingham NG1
5DD (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

(88) Date of publication of the international search report:
22 December 2005

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: INTRANASAL COMPOSITIONS COMPRISING ZOLPIDEM

(57) Abstract: The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention insomnia or the treatment of neurological disorders such as those arising from brain trauma, stroke and spinocerebellar ataxia or in the treatment of Parkinson's disease.

WO 2005/060945 A3